WO2006032342A3 - Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung - Google Patents

Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung Download PDF

Info

Publication number
WO2006032342A3
WO2006032342A3 PCT/EP2005/009124 EP2005009124W WO2006032342A3 WO 2006032342 A3 WO2006032342 A3 WO 2006032342A3 EP 2005009124 W EP2005009124 W EP 2005009124W WO 2006032342 A3 WO2006032342 A3 WO 2006032342A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbonyl compound
containing drug
drug
prophylaxis
therapy
Prior art date
Application number
PCT/EP2005/009124
Other languages
English (en)
French (fr)
Other versions
WO2006032342A2 (de
Inventor
Bertram Cezanne
Dieter Dorsch
Werner Mederski
Christos Tsaklakidis
Johannes Gleitz
Original Assignee
Merck Patent Gmbh
Bertram Cezanne
Dieter Dorsch
Werner Mederski
Christos Tsaklakidis
Johannes Gleitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Bertram Cezanne, Dieter Dorsch, Werner Mederski, Christos Tsaklakidis, Johannes Gleitz filed Critical Merck Patent Gmbh
Priority to JP2007531628A priority Critical patent/JP2008513387A/ja
Priority to EP05774750A priority patent/EP1791597A2/de
Priority to BRPI0515592-4A priority patent/BRPI0515592A/pt
Priority to AU2005287637A priority patent/AU2005287637A1/en
Priority to US11/575,711 priority patent/US20080003214A1/en
Priority to CA002581172A priority patent/CA2581172A1/en
Priority to MX2007003175A priority patent/MX2007003175A/es
Publication of WO2006032342A2 publication Critical patent/WO2006032342A2/de
Publication of WO2006032342A3 publication Critical patent/WO2006032342A3/de
Priority to IL181964A priority patent/IL181964A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Verwendung von verbindungen der Formel (I) Worin D, E, G, W, X, Y, T, R1 und R2 die in Patentanspruch 1 angegebene Bedeutung haben, zur Prophylaxe und/oder Therapie von thromboembolischen Erkrankungen.
PCT/EP2005/009124 2004-09-22 2005-08-24 Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung WO2006032342A2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2007531628A JP2008513387A (ja) 2004-09-22 2005-08-24 カルボニル化合物を含む医薬およびこの使用
EP05774750A EP1791597A2 (de) 2004-09-22 2005-08-24 Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung
BRPI0515592-4A BRPI0515592A (pt) 2004-09-22 2005-08-24 medicamentos compreendendo compostos de carbonila, e o uso dos mesmos
AU2005287637A AU2005287637A1 (en) 2004-09-22 2005-08-24 Carbonyl compound-containing drug and the use thereof
US11/575,711 US20080003214A1 (en) 2004-09-22 2005-08-24 Medicaments Comprising Carbonyl Compounds, And The Use Thereof
CA002581172A CA2581172A1 (en) 2004-09-22 2005-08-24 Carbonyl compound-containing drug and the use thereof
MX2007003175A MX2007003175A (es) 2004-09-22 2005-08-24 Medicamentos que contienen compuestos de carbonilo y su uso.
IL181964A IL181964A0 (en) 2004-09-22 2007-03-15 Medicaments comprising carbonyl compounds, and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004045796.4 2004-09-22
DE102004045796A DE102004045796A1 (de) 2004-09-22 2004-09-22 Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung

Publications (2)

Publication Number Publication Date
WO2006032342A2 WO2006032342A2 (de) 2006-03-30
WO2006032342A3 true WO2006032342A3 (de) 2007-01-11

Family

ID=35149637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/009124 WO2006032342A2 (de) 2004-09-22 2005-08-24 Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung

Country Status (18)

Country Link
US (1) US20080003214A1 (de)
EP (1) EP1791597A2 (de)
JP (1) JP2008513387A (de)
KR (1) KR20070054210A (de)
CN (1) CN101102818A (de)
AR (1) AR050945A1 (de)
AU (1) AU2005287637A1 (de)
BR (1) BRPI0515592A (de)
CA (1) CA2581172A1 (de)
DE (1) DE102004045796A1 (de)
EC (1) ECSP077401A (de)
IL (1) IL181964A0 (de)
MX (1) MX2007003175A (de)
PE (1) PE20060527A1 (de)
RU (1) RU2007115157A (de)
TW (1) TW200612910A (de)
WO (1) WO2006032342A2 (de)
ZA (1) ZA200703272B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004047254A1 (de) * 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
US20080194643A1 (en) * 2005-03-24 2008-08-14 Pfzer Inc Factor Xa Inhibitor Crystalline Forms
US7820699B2 (en) * 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
EA200802210A1 (ru) 2006-05-16 2009-06-30 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные пролинамиды, их получение и их применение в качестве лекарственных средств
US7811549B2 (en) * 2006-07-05 2010-10-12 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
ES2357340T3 (es) 2006-10-18 2011-04-25 Pfizer Products Inc. Compuestos de biaril éter urea.
WO2008049747A1 (en) * 2006-10-25 2008-05-02 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamides
US20080227823A1 (en) * 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
TW200911787A (en) * 2007-07-03 2009-03-16 Astrazeneca Ab New aza-bicyclohexane compounds useful as inhibitors of thrombin
KR20100114018A (ko) * 2007-11-30 2010-10-22 바이엘 쉐링 파마 악티엔게젤샤프트 헤테로아릴-치환된 피페리딘
US20090185973A1 (en) * 2008-01-22 2009-07-23 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
DE102009014484A1 (de) * 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
DE102009022896A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9056859B2 (en) 2010-10-29 2015-06-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
MX347391B (es) 2011-01-04 2017-04-25 Novartis Ag Compuestos de indol o análogos de los mismos útiles para el tratamiento de degeneración macular relacionada con la edad (amd).
US9062070B2 (en) 2011-08-19 2015-06-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2755656B1 (de) 2011-09-16 2016-09-07 Merck Sharp & Dohme Corp. Inhibitoren des renalen kaliumkanals der äusseren medulla
EP2771005B1 (de) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitoren des renalen kaliumkanals der äusseren medulla
WO2013062900A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773206B1 (de) 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitoren des renalen kaliumkanals der äusseren medulla
US9206199B2 (en) 2011-12-16 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP5903499B2 (ja) 2011-12-22 2016-04-13 ノバルティス アーゲー ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
JP6155332B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
EP2867227B1 (de) 2012-06-28 2018-11-21 Novartis AG Modulatoren des komplementweges und verwendungen davon
JP6273274B2 (ja) 2012-06-28 2018-01-31 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
JP6238980B2 (ja) 2012-07-12 2017-11-29 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
CN104640843A (zh) * 2012-07-19 2015-05-20 大日本住友制药株式会社 1-(环烷基羰基)脯氨酸衍生物
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
EP2925322B1 (de) 2012-11-29 2018-10-24 Merck Sharp & Dohme Corp. Inhibitoren des renalen kaliumkanals der äusseren medulla
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2956142B1 (de) 2013-02-18 2017-09-20 Merck Sharp & Dohme Corp. Inhibitoren des renalen kaliumkanals der äusseren medulla
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014150132A1 (en) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015065866A1 (en) 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
KR20160107322A (ko) 2014-01-14 2016-09-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 축합 ５－옥사졸리디논 유도체
CN104262340B (zh) * 2014-09-19 2016-08-31 济南诚汇双达化工有限公司 一种他达拉非的制备方法
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2018093695A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
EP3768378A4 (de) 2018-03-22 2021-11-17 InCarda Therapeutics, Inc. Neuartiges verfahren zur verlangsamung der ventrikulären rate
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045912A1 (en) * 2001-11-29 2003-06-05 Warner-Lambert Company Llc Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
DE10315377A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Carbonylverbindungen
WO2004087646A2 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Pyrrolidin -1,2-dicarbonsäure-1-(phenylamid) -2- (4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US6673817B1 (en) * 1999-05-24 2004-01-06 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE10314702A1 (de) * 2003-03-31 2004-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von Telmisartan
DE10329457A1 (de) * 2003-04-03 2005-01-20 Merck Patent Gmbh Ethinylprolinderivate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045912A1 (en) * 2001-11-29 2003-06-05 Warner-Lambert Company Llc Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
DE10315377A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Carbonylverbindungen
WO2004087646A2 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Pyrrolidin -1,2-dicarbonsäure-1-(phenylamid) -2- (4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen

Also Published As

Publication number Publication date
EP1791597A2 (de) 2007-06-06
ZA200703272B (en) 2009-05-27
CN101102818A (zh) 2008-01-09
AU2005287637A1 (en) 2006-03-30
RU2007115157A (ru) 2008-11-10
DE102004045796A1 (de) 2006-03-23
BRPI0515592A (pt) 2008-07-29
US20080003214A1 (en) 2008-01-03
PE20060527A1 (es) 2006-07-13
KR20070054210A (ko) 2007-05-28
WO2006032342A2 (de) 2006-03-30
ECSP077401A (es) 2007-05-30
AR050945A1 (es) 2006-12-06
TW200612910A (en) 2006-05-01
MX2007003175A (es) 2007-05-18
IL181964A0 (en) 2007-07-04
JP2008513387A (ja) 2008-05-01
CA2581172A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2006032342A3 (de) Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
WO2005111002A3 (de) Substituierte cycloalkylderivate zur behandlung von atemswegerkrankungen
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2004078144A3 (en) Diphenylethylene compounds and uses thereof
IL184051A (en) Acetylated GLP-1 compounds, containing and using pharmaceutical preparations
WO2004112719A3 (en) Chemical compounds
WO2007067559A3 (en) Antibacterial agents
WO2006072458A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2005077093A3 (en) Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
IL173204A0 (en) Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
TW200700392A (en) Novel compounds
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2004106293A3 (en) Oxazolyl - and thiazolyl - purine based tricyclic compounds.
WO2006028963A3 (en) Substituted heterocyclic compounds and uses thereof
WO2007097981A3 (en) Alpha carbolines and uses thereof
WO2006026747A3 (en) Diphenylethylene compounds and uses thereof
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
DE602004024213D1 (en) Aminopropanolderivate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005774750

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12007500390

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 181964

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/003175

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007531628

Country of ref document: JP

Ref document number: 2581172

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11575711

Country of ref document: US

Ref document number: 1020077006440

Country of ref document: KR

Ref document number: 200580031723.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 07028533

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 554590

Country of ref document: NZ

Ref document number: 1362/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005287637

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007115157

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005287637

Country of ref document: AU

Date of ref document: 20050824

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005774750

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11575711

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0515592

Country of ref document: BR